Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [scRNA-seq]

ABSTRACT: Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Be-havior and Therapy Resistance

ORGANISM(S): Homo sapiens

PROVIDER: GSE288878 | GEO | 2025/08/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [RNA-seq]

Project description:Overall, the LNCaP line has served as a remarkably versatile PC model, though the molecular characteristics of several important substrains have not been established nor compared in a systematic manner. In this study, we used genome-scale approaches to characterize the genomic and transcriptomic features of the parental LNCaP_FGC line, and a spectrum of 12 derivative models that have been deployed for studies of PC. These studies provide insights into the biochemical features that endow PC with the potential to resist AR-directed therapy and identify features that may underlie the metastatic and treatment resistant phenotypes observed in patients. An important but under-appreciated feature of LNCaP concerns the remarkable heterogeneity of the original LNCaP isolate and the current LNCaP_FGC line which was never subjected to clonal selection. This feature, coupled with the inherent DNA mismatch repair deficiency and genomic instability, has produced a remarkable spectrum of sublines that have provided important insights into PC pathobiology, but also challenge reproducibility and the accurate interpretation of experimental findings.

2025-08-21 | GSE288591 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ATAC-seq]

2025-08-21 | GSE288843 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [CRISPR Screen]

2025-08-21 | GSE289398 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance [ChIP-Seq]

2025-08-21 | GSE289031 | GEO

Comparative Molecular Analyses of LNCaP and Substrains Identify Drivers of Cancer Behavior and Therapy Resistance

Project description:This SuperSeries is composed of the SubSeries listed below. WGS data for this study is available at: PRJNA1219540

2025-08-21 | GSE288857 | GEO

Proteomic analysis of LNCaP wildtype (WT) and LNCaP OR51E2-knock out xenograft mouse tumor tissue

Project description:Quantitative proteomic analysis of tumor tissue lysates from wildtype LNCaP (WT) and LNCaP OR51E2-/- (KO) xenografts in male CIEA NOG mice.

2025-03-26 | PXD055974 | Pride

Cistrome analyses of AR stimulated by 0.1 nM DHT in LNCaP stable cell line overexpressing AR [ChIP-Seq]

Project description:The molecular drivers for the AR signaling reprogramming in castration-resistant prostate cancer remain to be determined. In this study, we hypothesize that increased AR expression in conjunction with lower-level androgens, which is a typical condition in prostate cancer cells receiving androgen deprivation therapy, is a major driving force of the reprogramming. To test this, we used LNCaP model with inducible overexpression of AR to examine the acute effects of AR overexpression stimulated by low-dose DHT (0.1nM) on AR cistrome.

2022-11-21 | GSE211639 | GEO

Transcriptome analyses of AR stimulated by 0.1 nM or 10 nM DHT in LNCaP stable cell line overexpressing AR [RNA-Seq]

2022-11-21 | GSE211638 | GEO

Comparative transcriptomic, epigenomic and immunological analyses identify drivers of disparity in high-grade serous ovarian cancer.

Project description:Black women face the highest mortality-to-incidence ratio from high grade serous ovarian cancer (HGSOC). This study investigated biological differences in HGSOC tumors from Black vs. White women. HGSOC from 35 Black and 31 White patients were analyzed by Infinium Methyation-EPIC array and RNA sequencing. 191 CpG sites were differentially methylated (FDR < 0.05, β value change> 10%) and 277 genes were differentially expressed (FDR < 0.05). Gene Ontology identified enriched pathways related to DNA damage response, p53/apoptosis signaling, and cholesterol/lipid metabolism directly connected with genes like INSR, FOXA1 and FOXB1. INSR and FOXA1 knockdown enhanced cisplatin sensitivity and inhibited cell proliferation and colony formation. Tumors from Black patients were infiltrated by fewer CD4+ naïve and regulatory T-cells. Overall, differences in DNA methylation, transcriptomic profiles and immune cell infiltration were detected in tumors from Black vs. White patients. Further investigation is warranted into how these differences may affect treatment response and outcomes in Black women.

| S-EPMC11612190 | biostudies-literature

A comparison between two Escherichia coli K-12 MG1655 substrains possessing different swimming motility

Project description:Substrains in Escherichia coli K-12 MG1655 can possess various swimming motility, which is mostly resulted from different expression levels of flhDC. Here, we studied the swimming motility of two MG1655 substrains, CY562 and CY570. Our results showed that CY562 had no insertion at the promoter region of flhDC and possessed no swimming motility. In contrast, CY570 had an IS-element insertion at the promoter region of flhDC and showed a hyper-motile phenotype. Transcriptomic data suggest that expression of flhDC and the other known flagella genes was much lower in CY562 than that in CY570. Moreover, CY562 possessed higher expression levels for genes involved in stress response, especially acid-stress response, than CY570. Consistently, CY562 showed a higher survival rate under acid stress than CY570. Our data indicate that there are mechanisms conversely regulating motility and stress response in E. coli.

2021-11-15 | GSE165438 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data